Clinical evaluation of recombinant human growth hormone injection in children with growth hormone deficiency

作     者：Ling HOU Xiaoping LUO Minlian DU Huamei MA Chunxiu GONG Yuchuan LI Shuixian SHEN Zhuhui ZHAO Li LIANG Guanping DONG Chaoying YAN Hongwei DU 

作者机构：Department of PediatricsTongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430030China Department of Pediatricsthe First Affiliated Hospital of Zhongshan UniversityGuangzhou 510080China Department of EndocrinologyBeijing Children's Hospital Affiliated to Capital Medical UniversityBeijing 100045China Department of Pediatric Endocrinology and MetabolismChildren's Hospital of Fudan UniversityShanghai 201102China The Affiliated Children's Hospital of Zhejiang University School of MedicineHangzhou 310003China Department of PediatricsThe First Hospital of Jilin UniversityChangchun 130021China 

出 版 物：《Frontiers of Medicine》 (医学前沿（英文版）)

年 卷 期：2009年第3卷第2期

页      面：171-176页

核心收录：

学科分类：1002[医学-临床医学] 100202[医学-儿科学] 10[医学] 

基　　金：supported by the Key Construction Project of Clinical Discipline of Ministry of Health of the People’s Republic of China(No.353) the National Science&Technology Pillar Program in the Eleventh Five-Year Plan Period(No.2006 BA105A07) 

主　　题：srecombinant human growth hormone injection growth hormone deficiency 

摘      要：Recombinant human growth hormone(rhGH)has been widely used in the clinical treatment of growth hormone defi*** simplify the injection process and increase drug compliance,application of the GH injection has become a new treatment plan in recent *** purpose of the current study was to evaluate the efficacy and safety of rhGH injection for the treatment of growth hormone deficiency(GHD)in children in *** a nationwide,noncomparative,prospective,randomized,open trial,31 children with confirmed complete GHD received subcutaneous injection of rhGH at 0.25 mg/kg$wk(0.107 IU/kg$d).The injection was given daily and the total weekly amount was separated into 6–7 *** patients were followed up at 3-month intervals and the treatment duration was 12 *** height(HT),annual growth velocity(GV),mean height standard deviation score(HT SDS),blood serum insulin-like growth factor I(IGF-I),insulin-like growth factor binding protein 3(IGFBP-3),and bone maturity before and after treatment were compared,and the safety of the treatment was *** mean HT,GV,and HT SDS were increased from 109.0�14 cm,2.7�0.9 cm/yr,and–4.62�1.46 at baseline to 121.8�13.4 cm,12.9�3.3 cm/yr,and–2.47�1.86 after 12 months of treatment,respectively(P0.001).At the same time,blood IGF-I and IGFBP-3 were increased significantly[41.27�64.43μg/L vs 159.21�167.92μg/L and 1540.00�1325.11 mg/L vs 3533.93�1413.82 mg/L,respectively(P0.001)].The bone age assessments performed 6 and 12 months after the treatment showed that no advanced bone maturation was *** serious adverse events occurred during the treatment,and the drug-related adverse events were mainly decreased thyroid *** conclude that rhGH injection is a safe and effective drug for treatment of growth hormone deficiency in children.